Literature DB >> 27261941

Partial Lamellar Sclerokeratouvectomy for Management of Epithelial Downgrowth.

Kavitha R Sivaraman1, Michael E Snyder.   

Abstract

PURPOSE: To describe a method of surgical management for cases of localized epithelial downgrowth (EDG).
METHODS: Single-center retrospective chart review of patients with histologically confirmed localized EDG of stratified squamous epithelium. Each patient underwent a partial lamellar sclerokeratouvectomy encompassing the area of suspected EDG. The main outcome measure was recurrence of EDG.
RESULTS: At a mean of 51 months of postoperative follow-up (range: 31-86), no patient had evidence of recurrent EDG. One eye developed worsening of preexisting glaucoma. All 3 eyes developed localized corneal edema, but only 1 required corneal transplantation.
CONCLUSIONS: EDG is a potentially devastating complication of intraocular surgery or penetrating injury. In cases of localized involvement of the anterior chamber structures, definitive management of EDG can be achieved via resection of the involved scleral, corneal, and uveal tissue. A lamellar approach minimizes tissue loss and maintains a structurally sound, pressurized globe.

Entities:  

Mesh:

Year:  2016        PMID: 27261941     DOI: 10.1097/ICO.0000000000000904

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  Intracameral 5-fluorouracil and viscous dispersive viscoelastic for diffuse epithelial downgrowth management in aphakia.

Authors:  Santiago Montolío-Marzo; Ester Fernández-López; Jose Vicente Piá-Ludeña; Juan María Davó-Cabrera; Enrique Antonio Alfonso-Muñoz; Cristina Peris-Martínez
Journal:  Int J Ophthalmol       Date:  2020-05-18       Impact factor: 1.779

2.  Management of severe epithelial versus fibrous downgrowth following trabeculectomy: Case report and literature review.

Authors:  Christos N Theophanous; Ema Avdagic; Asim V Farooq; Dimitra Skondra; Mary Qiu
Journal:  Am J Ophthalmol Case Rep       Date:  2021-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.